Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases
- 168 Downloads
New systemic treatments for advanced colorectal cancer have conferred a survival advantage, allowing patients to reach a median survival of almost 2 years. Due to this remarkable life extension, the incidence of brain metastases, though still low, is progressively increasing over time. There is little reported data on the optimal strategy to manage brain lesions from colorectal cancer.
To explore the role of an aggressive approach to colorectal cancer brain metastases, we retrospectively collected and analyzed data from 30 patients who underwent neurosurgical resection + whole-brain radiotherapy between March 1998 and December 2006. Univariate (logrank) and multivariate (Cox’s model) analyses were used to identify prognostic factors.
Median age at the time of surgery was 66 years, median ECOG PS was 1, most patients (87%) had concomitant lung and/or liver metastases. Median number of previous chemotherapies was two, with half of the patients being exposed both to oxaliplatin and irinotecan. A median of 27 Gy of radiotherapy were administered to 16 patients after resection. At the time of the analysis, 29 out of 30 patients had died, with a median survival time after brain metastasectomy of 167 days (8–682). Only one patient died within a month from surgery. Median survival was significantly longer in patients who received postsurgical radiotherapy (7.6 vs. 4.7 months, P = 0.014).
Neurosurgical management of symptomatic brain metastases from colorectal cancer is feasible, relatively safe, and offers a chance of prolonged survival. Patients who received radiotherapy after resection experienced a better outcome.
KeywordsColorectal cancer Brain metastases Radiotherapy Neurosurgery
- Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW (2006) Guidelines for resection of colorectal cancer liver metastases. Gut 55(S3:iii):1–8Google Scholar
- Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544. doi: 10.1200/JCO.2006.09.6305 PubMedCrossRefGoogle Scholar
- Grothey A, Sargent D (2004) Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used in first line. J Clin Oncol 22:1209–1214. doi: 10.1200/JCO.2004.11.037 PubMedCrossRefGoogle Scholar
- Grothey A, Sugrue M, Hedrick E, Purdie D, Yi J, Dong W et al (2007) Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (cCRC): results from a large observational study (BRiTE). ASCO Annual meeting proceedings part I. J Clin Oncol 25:4036Google Scholar
- http://www.cancer.gov/clinicaltrials as of June 24 2008
- Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maruel J et al (2007a) Randomized phase III trial of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: the CRYSTAL trial. ASCO Annual meeting proceedings part I. J Clin Oncol 25:4000Google Scholar
- Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al (2007b) Open-label phase II trial of panitumumav plus best supportive care compared with best supportive care alone in patients with cohemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664. doi: 10.1200/JCO.2006.08.1620 PubMedCrossRefGoogle Scholar